ALUMIS INC.
ALMS · XNASCIK 1847367fmd_18M50FDR3E8MRC8VJ803HNJG3RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | – | – | 24 |
| Research and development | 138 | 266 | 386 |
| Total operating expenses | 158 | 301 | 478 |
| Operating income | (158) | (301) | (454) |
| Other non-operating income (expense) | 3 | 7 | 202 |
| Income before taxes | – | (294) | (252) |
| Income tax expense | 0 | 0 | (9) |
| Net income from continuing operations | – | (294) | (243) |
| Net income | (155) | (294) | (243) |